All In Biotech

NDA 019034 · Fresenius Kabi USA

Dilaudid-Hp

Hydromorphone Hydrochloride · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jan 11, 1984

Approved uses

2

Original approval plus efficacy supplements

Registered trials

290

61 Phase 3, 22 recruiting

FAERS reports

91,827

85,087 serious, 28,204 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DILAUDID INJECTION Addiction, Abuse, and Misuse Because the use of DILAUDID INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of DILAUDID INJECTION, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of DILAUDID INJECTION are essential [see Warnings and Precautions ( 5.2 )]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids...

What it is approved for

From the label in effect Jul 15, 2026.

DILAUDID INJECTION is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Limitations of Use: • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration, and persist over the course of therapy [see Warnings and Precautions ( 5.2 )] , reserve opioid analgesics, including DILAUDID INJECTION for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. DILAUDID INJECTION is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. ( 1 ) Limitations of Use: • Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including DILAUDID INJECTION, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )

Mechanism: Hydromorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2009 Supplement 18 · Efficacy LabelLetter
  • Jan 11, 1984 Original approval · Type 3 - New Dosage Form · priority review
7 products under this application
  • DILAUDID-HP · HYDROMORPHONE HYDROCHLORIDE 250MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 0.5MG/0.5ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 4MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 1MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DILAUDID-HP · HYDROMORPHONE HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 0.2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydromorphone" as an intervention, any sponsor and status, largest first.

All 290 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence35,119
  • overdose23,079
  • pain22,354
  • emotional distress17,705
  • death14,926
  • drug withdrawal syndrome14,329
  • toxicity to various agents10,084
  • nausea4,811
  • drug ineffective4,543
  • fatigue3,652
  • vomiting3,601
  • off label use3,489

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004287
2005320
2006383
2007437
2008438
2009647
2010866
2011980
20121,400
20131,246
20141,380
20151,964
20162,588
20173,922
201823,055
20192,735
20208,703
202117,398
202215,695
20232,349
20242,204
20251,754
20261,074

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15). Check wholesaler for inventory

  • Current · updated Nov 3, 2026

    Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25). Other

  • Current · updated Nov 18, 2026

    Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11). Other

  • Current · updated Nov 18, 2026

    Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10). Check wholesalers for inventory

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dilaudid (Hydromorphone HCl)

2024 spending

$350K

Beneficiaries

253

757 claims

Per beneficiary

$1,384

$4.18 per unit

View as table
YearSpending
2020$1,667,512
2021$1,420,060
2022$1,121,656
2023$905,514
2024$350,270

Part B: Dilaudid* (Hydromorphone HCL/PF*) · HCPCS J1171

2024 spending

$99K

Beneficiaries

932

2,056 claims

Per beneficiary

$106

2024 ASP limit $0.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$98,543

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 568 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Dilaudid

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.